PE20011039A1 - Tiazoles e imidazopiridinas como inhibidores de la produccion de tnf - Google Patents

Tiazoles e imidazopiridinas como inhibidores de la produccion de tnf

Info

Publication number
PE20011039A1
PE20011039A1 PE2000001147A PE0011472000A PE20011039A1 PE 20011039 A1 PE20011039 A1 PE 20011039A1 PE 2000001147 A PE2000001147 A PE 2000001147A PE 0011472000 A PE0011472000 A PE 0011472000A PE 20011039 A1 PE20011039 A1 PE 20011039A1
Authority
PE
Peru
Prior art keywords
cycloalkyl
fluorophenyl
amino
alkyl
imidazopyridines
Prior art date
Application number
PE2000001147A
Other languages
English (en)
Spanish (es)
Inventor
Laszlo Revesz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9925441.9A external-priority patent/GB9925441D0/en
Priority claimed from GBGB9926173.7A external-priority patent/GB9926173D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20011039A1 publication Critical patent/PE20011039A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PE2000001147A 1999-10-27 2000-10-26 Tiazoles e imidazopiridinas como inhibidores de la produccion de tnf PE20011039A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9925441.9A GB9925441D0 (en) 1999-10-27 1999-10-27 Organic compounds
GBGB9926173.7A GB9926173D0 (en) 1999-11-04 1999-11-04 Organic compounds

Publications (1)

Publication Number Publication Date
PE20011039A1 true PE20011039A1 (es) 2001-10-30

Family

ID=26316029

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000001147A PE20011039A1 (es) 1999-10-27 2000-10-26 Tiazoles e imidazopiridinas como inhibidores de la produccion de tnf

Country Status (11)

Country Link
US (2) US6608072B1 (OSRAM)
EP (1) EP1224185B1 (OSRAM)
JP (1) JP2003512467A (OSRAM)
AR (1) AR029011A1 (OSRAM)
AT (1) ATE311385T1 (OSRAM)
AU (1) AU7922900A (OSRAM)
CO (1) CO5251463A1 (OSRAM)
DE (1) DE60024480T2 (OSRAM)
ES (1) ES2254238T3 (OSRAM)
PE (1) PE20011039A1 (OSRAM)
WO (1) WO2001030778A1 (OSRAM)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE342892T1 (de) 1998-08-29 2006-11-15 Astrazeneca Ab Pyrimidine verbindungen
JP2002523498A (ja) 1998-08-29 2002-07-30 アストラゼネカ・アクチエボラーグ ピリミジン化合物
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB9907658D0 (en) 1999-04-06 1999-05-26 Zeneca Ltd Chemical compounds
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
GB0004886D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0007371D0 (en) 2000-03-28 2000-05-17 Astrazeneca Uk Ltd Chemical compounds
US6943174B2 (en) 2000-06-14 2005-09-13 Warner-Lambert Company 6,5-Fused bicyclic heterocycles
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
GB0021726D0 (en) 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
US7199124B2 (en) 2001-02-02 2007-04-03 Takeda Pharmaceutical Company Limited JNK inhibitor
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
GB0113041D0 (en) 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
HRP20040098B1 (en) 2001-08-13 2012-08-31 Janssen Pharmaceutica N.V. 2,4,5-TRlSUBSTITUTED THIAZOLYL DERIVATIVES AND THEIR ANTIINFLAMMATORY ACTIVITY
TWI322807B (en) * 2002-01-07 2010-04-01 Eisai R&D Man Co Ltd Novel deazapurines and uses thereof
EP1707566A1 (en) * 2002-01-07 2006-10-04 Eisai Co., Ltd. Deazapurines and uses thereof
GB0205690D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
US7442697B2 (en) 2002-03-09 2008-10-28 Astrazeneca Ab 4-imidazolyl substituted pyrimidine derivatives with CDK inhibitory activity
GB0205688D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
JP4570955B2 (ja) * 2002-07-09 2010-10-27 バーテクス ファーマスーティカルズ インコーポレイテッド プロテインキナーゼ阻害活性を持つイミダゾール類
WO2004016267A1 (en) 2002-08-14 2004-02-26 Boehringer Ingelheim Pharmaceuticals, Inc. Anticoagulant and fibrinolytic therapy using p38 map kinase inhibitors
GB0226583D0 (en) * 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
WO2004076450A1 (en) 2003-02-27 2004-09-10 J. Uriach Y Compañia S.A. Pyrazolopyridine derivates
GB0311274D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
GB0311276D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
TWI334868B (en) 2003-06-03 2010-12-21 Nippon Kayaku Kk [1,2,4] triazoro [1,5-a] pyrimidine-2-ylurea derivative and use thereof
WO2005012298A1 (en) * 2003-07-30 2005-02-10 Cyclacel Limited Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors
JP4866610B2 (ja) * 2003-08-18 2012-02-01 富士フイルムファインケミカルズ株式会社 ピリジルテトラヒドロピリジン類およびピリジルピペリジン類
GB0401336D0 (en) * 2004-01-21 2004-02-25 Novartis Ag Organic compounds
EP1716150B1 (en) * 2004-01-22 2008-04-23 Amgen Inc. Substituted heterocyclic compounds and methods of use
TWI332003B (en) * 2004-01-30 2010-10-21 Lilly Co Eli Kinase inhibitors
TW200528101A (en) 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
EP1810972B1 (en) * 2004-11-10 2012-01-25 Ono Pharmaceutical Co., Ltd. Nitrogenous heterocyclic compound and pharmaceutical use thereof
WO2006137658A1 (en) * 2005-06-20 2006-12-28 Dongbu Hitek Co., Ltd. New substituted 1,3-thiazole derivatives or pharmaceutically acceptable salts thereof having immunosuppression and inflammation inhibitory acitivity, intermediate compounds or pharmaceutically acceptable salts thereof, a process for the preparation thereof, and pharmaceutical composition comprising the same
WO2007034278A2 (en) * 2005-09-19 2007-03-29 Pfizer Products Inc. Fused imidazole derivatives as c3a receptor antagonists
BRPI0616722A2 (pt) 2005-09-30 2012-12-25 Astrazeneca Ab composto ou um sal farmaceuticamente aceitÁvel ou um Éster hidrolisÁvel in vivo do mesmo, processo para preparar o mesmo, composiÇço farmacÊutica, uso de um composto ou um sal farmaceuticamente aceitÁvel ou um Éster hidrolisÁvel in vivo do mesmo, e, mÉtodos para produzir um efeito anti-proliferaÇço celular e um efeito inibidor cdk2, para tratar cÂncer, e para tratar doenÇas
US7968572B2 (en) 2005-10-03 2011-06-28 Ono Pharmaceuticals Co., Ltd. Nitrogen-containing heterocyclic compound and pharmaceutical application thereof
AU2008293532B2 (en) 2007-08-27 2014-08-28 Kineta Four Llc Antiviral drugs for treatment of Arenavirus infection
WO2009076140A1 (en) * 2007-12-13 2009-06-18 Smithkline Beecham Corporation Thiazole and oxazole kinase inhibitors
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
AU2009246687B2 (en) * 2008-05-13 2012-08-09 Irm Llc Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors
EP4585589A3 (en) * 2008-12-03 2025-11-19 The Scripps Research Institute Stem cell cultures
EP2198710A1 (de) 2008-12-19 2010-06-23 Bayer CropScience AG Verwendung von 5-Pyridin-4yl-(1,3)Thiazole zur Bekämpfung phytopathogener Pilze
BRPI1011058A2 (pt) * 2009-05-19 2015-08-25 Dow Agrosciences Llc Compostos e metodos controlar fungos
KR101668514B1 (ko) * 2011-02-25 2016-10-21 머크 샤프 앤드 돔 코포레이션 항당뇨병제로서 유용한 신규 시클릭 아자벤즈이미다졸 유도체
CN103145706B (zh) * 2012-11-16 2015-11-25 温州医学院 一类具有抗炎作用的咪唑并吡啶类化合物及其在制备抗炎药物中的应用
TWI623531B (zh) 2012-11-21 2018-05-11 Ptc治療公司 經取代反向嘧啶bmi-1抑制劑
WO2014172639A1 (en) * 2013-04-19 2014-10-23 Ruga Corporation Raf kinase inhibitors
JP6524094B2 (ja) * 2013-08-30 2019-06-05 ピーティーシー セラピューティクス, インコーポレイテッド 置換ピリミジンBmi−1阻害剤
US10584115B2 (en) 2013-11-21 2020-03-10 Ptc Therapeutics, Inc. Substituted pyridine and pyrazine BMI-1 inhibitors
GB201321739D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
KR102523430B1 (ko) 2014-08-04 2023-04-19 누에볼루션 에이/에스 염증성, 대사성, 종양성 및 자가면역성 질환의 치료에 유용한 피리미딘의 임의적 융합 헤테로시클릴-치환 유도체
CA2982446A1 (en) * 2015-03-18 2016-09-22 Bristol-Myers Squibb Company Tricyclic heterocyclic compounds useful as inhibitors of tnf
WO2016149436A1 (en) * 2015-03-18 2016-09-22 Bristol-Myers Squibb Company Substituted tricyclic heterocyclic compounds
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
WO2019142128A1 (en) * 2018-01-18 2019-07-25 Integral Biosciences Private Limited Dual inhibitors of alk5 and p38α map kinase
US12023335B2 (en) 2018-08-17 2024-07-02 Ptc Therapeutics, Inc. Method for treating pancreatic cancer
KR20210125471A (ko) 2018-10-05 2021-10-18 안나푸르나 바이오, 인코포레이티드 Apj 수용체 활성과 관련된 병태를 치료하기 위한 화합물 및 조성물
US11447479B2 (en) 2019-12-20 2022-09-20 Nuevolution A/S Compounds active towards nuclear receptors
UY38994A (es) 2019-12-20 2021-07-30 Nuevolution As Compuestos activos frente a receptores nucleares
AU2021245397A1 (en) 2020-03-31 2022-10-20 Nuevolution A/S Compounds active towards nuclear receptors
EP4126875A1 (en) 2020-03-31 2023-02-08 Nuevolution A/S Compounds active towards nuclear receptors

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6058981A (ja) * 1983-09-09 1985-04-05 Takeda Chem Ind Ltd 5−ピリジル−1,3−チアゾ−ル誘導体,その製造法およびそれを含んでなる医薬組成物
WO1993014082A1 (en) * 1992-01-13 1993-07-22 Smithkline Beecham Corporation Pyridyl substituted imidazoles
EP1306377A3 (en) * 1993-11-08 2003-05-07 Smithkline Beecham Corporation Pyridyl-oxazoles and their use as cytokines inhibitors
US5739143A (en) 1995-06-07 1998-04-14 Smithkline Beecham Corporation Imidazole compounds and compositions
IL118544A (en) * 1995-06-07 2001-08-08 Smithkline Beecham Corp History of imidazole, the process for their preparation and the pharmaceutical preparations containing them
CA2228050A1 (en) * 1995-08-10 1997-02-20 Harold G. Selnick 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use
HUP9903330A2 (hu) * 1996-11-19 2000-03-28 Amgen Inc. Gyulladásgátló hatású, aril- és heteroaril csoporttal szubsztituált kondenzált pirrolszármazékok, valamint ezeket tartalmazó gyógyászati készítmények
ZA9711092B (en) * 1996-12-11 1999-07-22 Smithkline Beecham Corp Novel compounds.
AU7132998A (en) * 1997-04-24 1998-11-13 Ortho-Mcneil Corporation, Inc. Substituted pyrrolopyridines useful in the treatment of inflammatory diseases
GB9713726D0 (en) * 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds
EP1025102B1 (en) * 1997-10-20 2004-05-19 F. Hoffmann-La Roche Ag Bicyclic kinase inhibitors
CA2302417A1 (en) * 1997-10-27 1999-05-06 Takeda Chemical Industries, Ltd. Adenosine a3 receptor antagonists
JP3990061B2 (ja) * 1998-01-05 2007-10-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 プリン誘導体および糖尿病の予防・治療剤としてのアデノシンa2受容体拮抗剤
AU4506399A (en) * 1998-06-05 1999-12-30 Novartis Ag Aryl pyridinyl thiazoles
JP2000119271A (ja) 1998-08-12 2000-04-25 Hokuriku Seiyaku Co Ltd 1h―イミダゾピリジン誘導体
CO5170501A1 (es) 1999-04-14 2002-06-27 Novartis Ag AZOLES SUSTITUIDOS UTILES PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR TNFa eIL-1 Y ENFERMEDADES DEL METABOLISMO OSEO
JP3333774B2 (ja) * 1999-04-23 2002-10-15 武田薬品工業株式会社 5−ピリジル−1,3−アゾール化合物、その製造法及び用途
CN1156471C (zh) 1999-04-23 2004-07-07 武田药品工业株式会社 5-吡啶基-1,3-唑系化合物、它们的制备方法及用途
US6492516B1 (en) 1999-05-14 2002-12-10 Merck & Co., Inc. Compounds having cytokine inhibitory activity

Also Published As

Publication number Publication date
EP1224185B1 (en) 2005-11-30
US6891039B2 (en) 2005-05-10
ES2254238T3 (es) 2006-06-16
ATE311385T1 (de) 2005-12-15
DE60024480T2 (de) 2006-07-27
US20040082604A1 (en) 2004-04-29
DE60024480D1 (de) 2006-01-05
EP1224185A1 (en) 2002-07-24
JP2003512467A (ja) 2003-04-02
AU7922900A (en) 2001-05-08
CO5251463A1 (es) 2003-02-28
WO2001030778A1 (en) 2001-05-03
AR029011A1 (es) 2003-06-04
US6608072B1 (en) 2003-08-19

Similar Documents

Publication Publication Date Title
PE20011039A1 (es) Tiazoles e imidazopiridinas como inhibidores de la produccion de tnf
PE20001484A1 (es) Derivados de naftalen-1-ilo urea y acido carbamico
US5296486A (en) Leukotriene biosynthesis inhibitors
PE20081845A1 (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
PE20080403A1 (es) Derivados heterociclicos fusionados y metodos de uso
PE20121509A1 (es) Compuestos de triazolopiridinas como inhibidores de quinasa mps-1
HRP20192274T1 (hr) Novi derivati oktahidro-pirolo[3,4−c]-pirola i njihovi analozi kao inhibitori autotaksina
PE20060374A1 (es) Inhibidores de cinasa heterociclicos fusionados
ECSP088867A (es) Derivados de pirimidina como inhibidores de fi3q
CA2384101A1 (en) Tyrosine kinase inhibitors
PE20090900A1 (es) Derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol como inhibidores del receptor del factor de creciemiento de hepatocitos (met), su procedimiento de preparacion y una composicion farmaceutica que los contiene
ATE443701T1 (de) Heterocyclische, ein azol enthaltende sulfonamidinhibitoren der beta-amyloid-produktion
ME02100B (me) Derivati 4-aminopirimidina i njihova primena kao antagonista adenozinskog a2a receptora
PE20090774A1 (es) Compuestos heterociclicos como moduladores de la enzima dgat1
PE20091818A1 (es) DERIVADOS POLISUSTITUIDOS DE 2-ARIL-6-FENIL-IMIDAZO[1,2-a] PIRIDINAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA
PE20110944A1 (es) DERIVADOS DE PIRAZOLO[3,4-d]PIRIMIDINA COMO INHIBIDORES PDE1
NO20081464L (no) 1-heterocyklusulfonyl, 2-aminometyl, 5-(hetero-)aryl subsidiert 1-H-pyrrol-derivater som syresekresjonsinhibitorer
DK419086A (da) Heterocykliske substituerede indoler, mellemprodukter, fremgangsmaader til fremstilling heraf og laegemidler
PE20001583A1 (es) Derivados de la 1-arenosulfonil-2-arilo-pirrolidina y de la piperidina
PE20080345A1 (es) Derivados de piperazina como agonistas del receptor de gpr38
AR035111A1 (es) Procedimiento para preparar un compuesto de pirimidinona
PE20091243A1 (es) Compuesto heterociclico fusionado
PE20081735A1 (es) Derivados de 1-oxa-3[4,5]decan-2-ona en el tratamiento de trastornos alimenticios
AR109650A1 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
PE20020603A1 (es) Derivados de pirimidina como antagonista del receptor del neuropeptido y (npy)

Legal Events

Date Code Title Description
FC Refusal